Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Spratt

Showing results (551-560 of 666) with videos related to

Pageof 67
Sort By:
Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
International Journal of Surgical Pathology|October 17, 2022
Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal NeoplasmsRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate CancerDaniel E Spratt, Mohammed Alshalalfa, Nick Fishbane, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
European Urology|October 8, 2024
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover TrialTodd M Morgan, Stephanie Daignault-Newton, Daniel E Spratt, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Pageof 67

Showing results (551-560 of 666) with videos related to

Sort By:
Pageof 67
Cancer|April 15, 2023
A novel prostate cancer subtyping classifier based on luminal and basal phenotypesAdam B Weiner, Yang Liu, Alex Hakansson, et al.
Prostate Cancer and Prostatic Diseases|November 14, 2019
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomyJoseph Marascio, Daniel E Spratt, Jingbin Zhang, et al.
Practical Radiation Oncology|November 26, 2019
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT TrialJohn L Gore, Marguerite du Plessis, Jingbin Zhang, et al.
International Journal of Surgical Pathology|October 17, 2022
Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal NeoplasmsRahul Mannan, Xiaoming Wang, Pushpinder S Bawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2017
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer SubgroupDavid P Labbé, Christopher J Sweeney, Myles Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate CancerDaniel E Spratt, Mohammed Alshalalfa, Nick Fishbane, et al.
International Journal of Radiation Oncology, Biology, Physics|January 3, 2023
Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized TrialsPaul L Nguyen, Huei-Chung Rebecca Huang, Daniel E Spratt, et al.
European Urology Oncology|July 17, 2025
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 TrialRyan M Phillips, James A Proudfoot, Elai Davicioni, et al.
European Urology|October 8, 2024
Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover TrialTodd M Morgan, Stephanie Daignault-Newton, Daniel E Spratt, et al.
Cancer|December 20, 2025
Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trialsGeorges Gebrael, Neeraj Agarwal, Alicia K Morgans, et al.
Pageof 67